Caris Molecular Intelligence Registry
Launched by CARIS SCIENCE, INC. · Feb 9, 2016
Trial Information
Current as of May 27, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age greater than or equal to 18 years, and
- • Solid Tumor analyzed by Caris Molecular Intelligence™ Service Profile(s) and/or Caris Next-Generation Sequencing
- Exclusion Criteria:
- • Individual test orders; defined as single biomarker assessment
- • Due to the complexity of state and federal requirements governing the participation of prisoners in research, prisoner-patients shall not be approached for participation in the Registry.
About Caris Science, Inc.
Caris Science, Inc. is a leading biotechnology company dedicated to advancing precision medicine through innovative diagnostic solutions. With a focus on molecular profiling, Caris utilizes comprehensive genomic and proteomic analyses to enhance the understanding of cancer and other complex diseases. The company aims to empower clinicians with actionable insights that guide personalized treatment strategies, ultimately improving patient outcomes. Committed to research and development, Caris collaborates with academic institutions, pharmaceutical companies, and healthcare providers to drive breakthroughs in targeted therapies and biomarker discovery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials